Ate-Bev Early Response Prediction Model in Advanced HCC
NCT05763277
·
clinicaltrials.gov ↗
RECRUITING
Status
170
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Atezolizumab-bevacizumab
Response Evaluation
Interventions
DIAGNOSTIC_TEST:
Early response evaluation
Sponsor
Seoul National University Hospital